14 recruiting, 9 completed, 6 active not recruiting, 3 terminated. 23 Phase 2, 15 Phase 1, 5 Phase 3, 2 Not applicable, 1 Phase 4.
Follow Precursor B-Cell Lymphoblastic Leukemia-Lymphoma: new trials by email Literature Review of Precursor B-Cell Lymphoblastic Leukemia-Lymphoma trials Research Report on Precursor B-Cell Lymphoblastic Leukemia-Lymphoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Genetically Engineered Cells (BAFFR-CAR T Cells) for the Treatment of Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia and B-cell Lymphoblastic Lymphoma Autologous BAFFR-targeting CAR T Cells, Biospecimen Collection, Bone Marrow Aspiration - Recurrent B Acute Lymphoblastic Leukemia, Recurrent B Lymphoblastic Lymphoma | Phase 1 | Recruiting | City of Hope Medical Center | 16 | 2027-04-17 | 2026-11-13 |
| HEM-iSMART E: Capivasertib + Venetoclax + Dexamethasone in Pediatric Patients With Relapsed or Refractory Hematological Malignancies Capivasertib, Venetoclax, Dexamethasone - Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) Recurrent | Phase 1 / Phase 2 | Not yet recruiting | Princess Maxima Center for Pediatric Oncology | 42 | 2026-10-01 | 2025-09-16 |
| A Study of Injectable BLB101 and Blincyto® in Adult Participants With R/R CD19+ B-ALL BLB101 for Injection, Blinatumomab for Injection - Precursor B-cell Acute Lymphoblastic Leukemia | Phase 3 | Not yet recruiting | Institute of Hematology & Blood Diseases Hospital, China | 212 | 2026-08-09 | 2026-07-23 |
| BEBT-908 Plus Chemotherapy Treatment for CR MRD-Positive MEF2D-Rearranged and Pre-B Acute Lymphoblastic Leukemia Patients BEBT-908, Cyclophosphamide, Vincristine - Acute Lymphoblastic Leukemia | Phase 2 | Recruiting | Ruijin Hospital | 23 | 2025-12-15 | 2026-11-17 |
| Evaluating the Effects of Hemoglobin Threshold-specific Packed Red Blood Cell Transfusions on Quality of Life and Functional Outcomes in Patients With High-grade Myeloid Neoplasms, Acute Myeloid Leukemia, or B Acute Lymphoblastic Lymphoma/Leukemia Activity Tracking, Biospecimen Collection, Cognitive Assessment - Acute Myeloid Leukemia, B Acute Lymphoblastic Leukemia | Not applicable | Recruiting | University of Washington | 50 | 2025-10-15 | 2026-08-19 |
| HEM-iSMART-B: Dasatinib + Venetoclax + Dexamethasone + Cyclophosphamide and Cytarabine in Pediatric Patients With Relapsed or Refractory Hematological Malignancies Dasatinib, Venetoclax, Dexamethasone - Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) Recurrent | Phase 1 / Phase 2 | Recruiting | Princess Maxima Center for Pediatric Oncology | 26 | 2025-10-01 | 2025-09-16 |
| HEM-iSMART-C: Ruxolitinib + Venetoclax + Dexamethasone + Cyclophosphamide and Cytarabine in Pediatric Patients With Relapsed or Refractory Hematological Malignancies Ruxolitinib, Venetoclax, Dexamethasone - Acute Lymphoblastic Leukemia, in Relapse, Lymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) Recurrent | Phase 1 / Phase 2 | Recruiting | Princess Maxima Center for Pediatric Oncology | 26 | 2025-10-01 | 2025-09-16 |
| Venetoclax Combined With Olverembatinib and Predinisone in Treating Ph+ B-ALL Venetoclax, Olverembatinib, Predinisone - Precursor B-Cell Acute Lymphoblastic Leukemia | Phase 2 | Recruiting | First Affiliated Hospital of Zhejiang University | 36 | 2024-12-01 | 2024-12-31 |
| Nanobody-Based CD19/CD22 Tandem Dual CAR-T Therapy for R/R B-ALL Nanobody-Based CD19/CD22 Tandem Dual CAR-T - Precursor B-Cell Lymphoblastic Leukemia-Lymphoma | Phase 1 / Phase 2 | Recruiting | Peking University People's Hospital | 50 | 2024-11-14 | 2026-03-30 |
| Blinatumomab Plus Reduced-dose Chemotherapy in Treating B-ALL Blinatumomab plus Reduced-dose Chemotherapy - Precursor B-Cell Acute Lymphoblastic Leukemia | Phase 2 | Recruiting | First Affiliated Hospital of Zhejiang University | 20 | 2024-10-17 | 2024-12-19 |
| Blinatumomab Plus Venetoclax Sequenced With Inotuzumab Ozogamicin in Treating B-ALL Dexamethasone, Blinatumomab, Venetoclax - Precursor B-Cell Lymphoblastic Leukemia | Phase 2 | Recruiting | First Affiliated Hospital of Zhejiang University | 20 | 2024-08-15 | 2024-08-15 |
| CD19-targeted CAR T Cell Autotransfusion for the Treatment of Recurrent/Refractory B-cell Acute Lymphoblastic Leukemia/Lymphoblastic Lymphoma in Children With CD19+ CAR T cell injection - B Lymphocytic Leukemia, B Lymphoblastic Lymphoma | Not applicable | Recruiting | Zhu Xiaofan | 60 | 2024-02-01 | 2024-04-09 |
| HEM iSMART-D: Trametinib + Dexamethasone + Chemotherapy in Children With Relapsed or Refractory Hematological Malignancies Trametinib, Dexamethasone, Cyclophosphamide - Acute Lymphoblastic Leukemia, in Relapse, Lymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) Recurrent | Phase 1 / Phase 2 | Recruiting | Princess Maxima Center for Pediatric Oncology | 26 | 2023-11-14 | 2025-09-16 |
| HEM-iSMART-A: Decitabine / Venetoclax and Navitoclax in Pediatric Patients With Relapsed or Refractory Hematological Malignancies Decitabine, Venetoclax, Navitoclax - Acute Lymphoblastic Leukemia, in Relapse, Lymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) Recurrent | Phase 1 / Phase 2 | Withdrawn | Princess Maxima Center for Pediatric Oncology | 2023-10-01 | 2024-06-21 | |
| Comparing Inotuzumab Combined With Low Intensity Chemotherapy Plus Blinatumomab to Usual Chemotherapy Plus Blinatumomab in Older Adults With CD22+ B-cell Acute Lymphoblastic Leukemia Cyclophosphamide, Vincristine, Dexamethasone - B Acute Lymphoblastic Leukemia, B Lymphoblastic Lymphoma | Phase 2 | Active not recruiting | Alliance for Clinical Trials in Oncology | 68 | 2023-06-09 | 2026-07-10 |
| FT819 in Subjects With B-cell Malignancies FT819, Cyclophosphamide, Fludarabine - Lymphoma, B-Cell, Chronic Lymphocytic Leukemia | Phase 1 | Active not recruiting | Fate Therapeutics | 54 | 2021-07-12 | 2026-03-19 |
| Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy Biospecimen Collection, Blinatumomab, Bone Marrow Aspiration - B Acute Lymphoblastic Leukemia, B Lymphoblastic Lymphoma | Phase 3 | Recruiting | Children's Oncology Group | 5951 | 2019-10-31 | 2026-08-25 |
| Inotuzumab Ozogamicin and Chemotherapy in Treating Patients With Recurrent or Refractory B-cell Acute Lymphoblastic Leukemia Etoposide, Doxorubicin, Vincristine - Recurrent B Acute Lymphoblastic Leukemia, Recurrent B Lymphoblastic Lymphoma | Phase 1 | Completed | University of Washington | 24 | 2019-09-24 | 2023-07-06 |
| A Study to Investigate Blinatumomab in Combination With Chemotherapy in Patients With Newly Diagnosed B-Lymphoblastic Leukemia Asparaginase Erwinia chrysanthemi, Blinatumomab, Cyclophosphamide - B Acute Lymphoblastic Leukemia, B Lymphoblastic Lymphoma | Phase 3 | Active not recruiting | National Cancer Institute (NCI) | 6720 | 2019-07-03 | 2026-11-12 |
| A Study Of Two Inotuzumab Ozogamicin Doses in Relapsed/ Refractory Acute Lymphoblastic Leukemia Transplant Eligible Patients inotuzumab ozogamicin-dose level 2, Inotuzumab ozogamicin-dose level 1 - Leukemia, Precursor b-Cell Lymphoblastic Leukemia-Lymphoma | Phase 4 | Completed | Pfizer | 102 | 2019-07-01 | 2023-11-22 |
Showing 20 of 38. Sign in to see all of them.
Precursor Cell Lymphoblastic Leukemia-Lymphoma (20) · Burkitt Lymphoma (16) · Leukemia (9) · Precursor T-Cell Lymphoblastic Leukemia-Lymphoma (8) · Recurrence (7) · Lymphoma, B-Cell (5) · Lymphoma, Large B-Cell, Diffuse (4) · Leukemia, Myeloid, Acute (3) · Lymphoma, Follicular (3) · Down Syndrome (2) · Leukemia, Biphenotypic, Acute (2) · Lymphoma (2) · Neoplasm, Residual (2) · Central Nervous System Neoplasms (1)
Hematologic Diseases (38) · Hemic and Lymphatic Diseases (38) · Immune System Diseases (38) · Immunoproliferative Disorders (38) · Lymphatic Diseases (38) · Lymphoproliferative Disorders (38) · Neoplasms (38) · Neoplasms by Histologic Type (38) · Leukemia, Lymphoid (37) · Leukemia (29) · Lymphoma, Non-Hodgkin (18) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (18) · DNA Virus Infections (16) · Epstein-Barr Virus Infections (16) · Herpesviridae Infections (16)
Cyclophosphamide (15) · Dexamethasone (13) · Cytarabine (11) · Vincristine (11) · Methotrexate (9) · Doxorubicin (7) · Inotuzumab Ozogamicin (7) · blinatumomab (7) · venetoclax (7) · Prednisone (6) · merphos (6) · pegaspargase (6) · Calcium Dobesilate (5) · Mercaptopurine (5) · Specimen Handling (5)
Princess Maxima Center for Pediatric Oncology (5) · Children's Oncology Group (3) · First Affiliated Hospital of Zhejiang University (3) · University of Washington (3) · Medical College of Wisconsin (2) · Seagen Inc. (2) · Alliance for Clinical Trials in Oncology (1) · Ankara Children's Health and Diseases Hematology and Oncology Training and Research Hospital (1) · Asan Medical Center (1) · Assistance Publique - Hôpitaux de Paris (1) · City of Hope Medical Center (1) · ECOG-ACRIN Cancer Research Group (1) · Fate Therapeutics (1) · Institut de Cancérologie de la Loire (1) · Institute of Hematology & Blood Diseases Hospital, China (1)
United States (19) · China (6) · Puerto Rico (6) · France (5) · Australia (4) · Ireland (4) · Netherlands (4) · Spain (4) · Austria (3) · Belgium (3) · Canada (3) · Denmark (3) · Finland (3) · Germany (3) · Israel (3)
Michel Zwaan, Prof. Dr. (3) · Andrej Lissat, MD PhD (2) · Mary Horowitz, MD, MS (2) · Paco Bautista, MD PhD (2) · Ryan Cassaday (2) · Ana Kostic, MD (1) · Andrej Lissat, MD, PhD (1) · Anna Halpern, MD (1) · Anne L Angiolillo (1) · Chantal Le Guellec, PharmD, PhD (1) · Dae-Young Kim, MD, PhD (1) · Elias Jabbour (1) · Emmanuelle Tavernier, MD (1) · Eric Feldman, MD (1)
PMID 41671463, PMID 35622074, PMID 21527516, PMID 24862638, PMID 23233571, PMID 24433481, PMID 31969338, PMID 33191168, PMID 33411585, PMID 33844429, PMID 35007127, PMID 36279879, PMID 37890117, PMID 38722664, PMID 39121442, PMID 39415930, PMID 39651791, PMID 39882642, PMID 40315406, PMID 42154791
U10CA180886 (4), U01HL069294 (2), U24CA076518 (2), 2009 (1), 2018 (1), 2025 (1), P30CA015704 (1), P30CA033572 (1), U10CA098543 (1), U10CA180820 (1), U10CA180821 (1)